FRED X System
Microvention, Inc. · Decision date Sep 18, 2025
What did the FDA approve?
FDA records P180027/S014 as a supplement to PMA P180027, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 18, 2025.
FDA approval order statement
Approval of claims regarding reduced acute material thrombogenicity supported by in-vitro testing on a proprietary device surface modification.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 18, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P180027/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Microvention, Inc.
- Product code
- OUT
- Decision code
- APPR
- Decision date
- Sep 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial aneurysm flow diverter.
- Applicant
- Microvention, Inc.
- Product code
- OUT
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180027/S014 received
Application receipt date recorded by FDA.
P180027/S014 · FDA decision
Real-Time Process
P180027/S012 · Related supplement
Flow Re-Direction Endoluminal Device (FRED) X System
P180027/S013 · Related supplement
Flow Re-Direction Endoluminal Device (FRED) System
Timeline entries are records held by MedtechLedger for P180027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA supplement | Sep 20, 2025 | FDA | |
| Microvention, Inc. | PMA supplement | Nov 2, 2025 | FDA |
Explore the linked device profile
Other records with product code OUT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Surpass Elite Flow DiverterP170024/S027 | Stryker Neurovascular | PMA supplement | Aug 28, 2026 | FDA |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jul 21, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jun 26, 2026 | FDA | |
Surpass Evolve; Surpass Elite FDSP170024/S026 | Stryker Neurovascular | PMA supplement | Jun 26, 2026 | FDA |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | May 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Microvention, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 35 Enterpricse, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P180027/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




